Pharmaceutical News

RSS

Vertical Pharmaceuticals, Nautilus Neurosciences sign co-promotion agreement for Lorzone

Vertical Pharmaceuticals, Inc. today announced that Vertical and Nautilus Neurosciences have entered into a co-promotion agreement for Lorzone (chlorzoxazone tablets, USP), a safe, effective, and fast-acting muscle relaxant that is not associated with significant sedation or drowsiness.

11 Jun 2013

Findings link antihistamine use to adverse pregnancy outcomes

Women with a severe form of morning sickness who take antihistamines to help them sleep through their debilitating nausea are significantly more likely to experience adverse pregnancy outcomes, including low birth weight babies and premature births, a UCLA study has found.

11 Jun 2013

Novel approach to pain therapy paves way for lower dosage painkillers

For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.

11 Jun 2013

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

ViroPharma Incorporated today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral disease in patients with impaired cell mediated immunity.

11 Jun 2013

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include depression, fatigue, nausea and change of appearance.

11 Jun 2013

African medicinal plants contain chemicals that may help stop spread of cancer cells

African medicinal plants contain chemicals that may be able to stop the spread of cancer cells. This is the conclusion of researchers following laboratory experiments conducted at Johannes Gutenberg University Mainz (JGU).

10 Jun 2013

Mandatory influenza vaccination does not lead to excessive voluntary termination

Mandatory influenza (flu) vaccination, as a condition of employment, did not lead to excessive voluntary termination, according to a four-year analysis of vaccination rates at Loyola University Medical Center in Maywood, IL.

10 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Drug used to control Type II diabetes can help repair spinal cords of mice suffering from inherited disease

A drug used to control Type II diabetes can help repair the spinal cords of mice suffering from the inherited disease adrenoleukodystrophy which, untreated, leads eventually to a paralysis, a vegetative state and death.

10 Jun 2013

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

10 Jun 2013

Common antidepressant medications may impair a form of learning, new report suggests

An interesting new report of animal research published in Biological Psychiatry suggests that common antidepressant medications may impair a form of learning that is important clinically.

10 Jun 2013

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.

10 Jun 2013

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Edge Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products for acute, fatal or debilitating conditions, announced today that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug application for EG-1962, a novel bio-absorbable nimodipine microparticle formulation.

10 Jun 2013

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1

10 Jun 2013

Whitehead Institute researchers identify drug target for anemia

Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.

10 Jun 2013

FDA panel loosens Avandia safety restrictions

Despite some concern over whether the diabetes drug Avandia can increase heart problems, an FDA panel Thursday loosened restrictions on how doctors can prescribe the drug.

10 Jun 2013

Drug regulators slow to pursue concerns about potential adverse effects of new diabetes drugs

The BMJ and Channel 4 Dispatches investigated and found that evidence suggesting potential harm from the drugs in industry studies has not been published.

10 Jun 2013

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

A team of researchers has made a significant discovery which may have a dramatic impact on children stricken with Tay-Sachs disease, a degenerative and fatal neurological condition that often strikes in the early months of life.

7 Jun 2013

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.

7 Jun 2013

Aflibercept drug used for AMD shows no added benefit over current standard therapy

The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy.

7 Jun 2013

Pharmaceutical News

Vertical Pharmaceuticals, Nautilus Neurosciences sign co-promotion agreement for Lorzone

Findings link antihistamine use to adverse pregnancy outcomes

Novel approach to pain therapy paves way for lower dosage painkillers

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

African medicinal plants contain chemicals that may help stop spread of cancer cells

Mandatory influenza vaccination does not lead to excessive voluntary termination

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

Drug used to control Type II diabetes can help repair spinal cords of mice suffering from inherited disease

NanoViricides files Orphan Drug application with FDA for DengueCide

Common antidepressant medications may impair a form of learning, new report suggests

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

Whitehead Institute researchers identify drug target for anemia

FDA panel loosens Avandia safety restrictions

Drug regulators slow to pursue concerns about potential adverse effects of new diabetes drugs

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

Aflibercept drug used for AMD shows no added benefit over current standard therapy

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News